GlassScriptPhysician profile
Emily W Kane
NPI 1386855468
$7,523.25
in general payments reported to CMS, 2019-2025
18 companies · $2,848 in 2025
The $2,848 reported for 2025 was more than what 97% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,709 · 2022: $605 · 2023: $302 · 2024: $2,059 · 2025: $2,848.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,354 · Honoraria: $1,750 · Consulting Fee: $1,050 · Education: $54.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,354.33 |
| Honoraria | $1,750.00 |
| Consulting Fee | $1,050.00 |
| Education | $54.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alk-Abello, INC | $4,611.38 | 2021-2025 | Odactra, Grastek, Ragwitek |
| Glaxosmithkline, LLC. | $724.07 | 2021-2025 | Nucala |
| Regeneron Healthcare Solutions, INC. | $704.16 | 2023-2025 | Dupixent |
| Genzyme Corporation | $417.53 | 2023-2025 | |
| Ars Pharmaceuticals Operations, INC. | $319.52 | 2025 | Neffy |
| Abbvie INC. | $150.17 | 2022-2025 | |
| Novo Nordisk INC | $140.85 | 2022 | |
| Intersect Ent, INC. | $103.19 | 2022 | |
| Inspire Medical Systems, INC. | $76.80 | 2024-2025 | Inspire |
| Pfizer INC. | $73.50 | 2025 | |
| Sanofi-Aventis U.S. LLC | $54.95 | 2024 | |
| Astrazeneca Pharmaceuticals LP | $47.68 | 2025 | Tezspire |
| Novartis Pharmaceuticals Corporation | $22.98 | 2025 | |
| Kaleo, INC. | $18.31 | 2021 | |
| Hikma Pharmaceuticals USA | $15.86 | 2024 | Ryaltris |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Blueprint Medicines Corporation | $15.34 | 2025 | Ayvakit |
| Merck Sharp & Dohme LLC | $13.76 | 2023 | |
| Optinose US, INC. | $13.20 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Emily Kane listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.